Vantage MedTech has restructured its leadership team to support its upcoming growth phase.

Carlo W. Colesanti is now president and CEO and Jim Bartel has transitioned into the chief commercial officer role, leveraging his knowledge of the company’s service offering and decades of experience leading successful commercial functions across engineering- and manufacturing-focused service providers. Additionally, Randy Barko has been named executive board chairman—a position that will likely benefit from his decades of senior leadership and board-level experience in the medical device outsourcing industry.

Backed by Boston-based private equity firm Ampersand Capital Partners, this new leadership structure positions Vantage MedTech to build on its strong foundation, driving continued growth and innovation across the medtech industry, according to the company.

“Carlo brings deep operational expertise, extensive experience scaling specialty manufacturing businesses, and a strong alignment with Vantage MedTech’s culture and purpose,” Barko said. “It’s an honor to step into the role of executive chairman, and with Carlo’s leadership and Jim’s continued contributions, I’m confident we are well-positioned to accelerate the company’s next phase of growth.”

Colesanti has more than 30 years of global leadership experience in medical device services and specialty chemicals. He was previously president, CEO, and board member of NextPhase Medical Devices, where he led the company through significant growth and a successful sale in 2023. Colesanti’s experience in scaling businesses, executing M&A strategies, and building high-performing teams will help position Vantage for its next chapter of innovation and growth, company bigwigs claim.

“Vantage has assembled an exceptionally talented team of experts spanning software, mechanical, electrical, industrial, and systems engineering. Combined with its customer-centric service platform, it has earned the company a reputation of expertly pairing development and manufacturing services for complex electromechanical medical devices,” Colesanti stated. “I’m excited to work closely with the leadership team to build on this foundation—expanding our capabilities, further differentiating our offerings, and delivering value to our clients and stakeholders.”

Since its founding, Vantage MedTech has served both emerging and established medical-technology companies across the product life cycle, delivering concept-to-commercial services—from feasibility and prototyping through clinical and commercial manufacturing and aftermarket support. With facilities in Lenexa, Kan.; and Moonachie, N.J.; the company’s Advantage Platforms help companies achieve accelerated development timelines and scalable manufacturing capacity.

Vantage MedTech has experienced several years of strong momentum, including expanded service lines, operational enhancements, and strengthening client partnerships.

Vantage MedTech provides design and manufacturing services, helping advance medical technologies from concept through to product realization. Partnering with medtech startups and large medical device companies, Vantage MedTech offers feasibility support, product development and prototyping, clinical and commercial manufacturing, and after-market services to support all product life cycle phases. Its clients can leverage the proprietary Advantage Platforms, accelerating product development timelines. The firm’s manufacturing approach is structured to serve changing client needs, supporting small-quantity clinical or first-in-human builds, and can scale to accommodate full launch quantities.

Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With hubs in Boston, Amsterdam, and London, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous companies across each of the firm’s core healthcare sectors.